We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00621218
Recruitment Status : Completed
First Posted : February 22, 2008
Last Update Posted : December 18, 2008
Information provided by:
Coria Laboratories, Ltd.

Brief Summary:
To compare the efficacy and safety of tretinoin gel 0.05% to its vehicle when dosed once or twice daily in female subjects with rosacea.

Condition or disease Intervention/treatment Phase
Rosacea Drug: tretinoin gel 0.05% Drug: vehicle Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Study to Compare Tretinoin Gel, 0.05% to Tretinoin Gel Vehicle When Dosed Once or Twice Daily in Female Subjects With Classical Rosacea
Study Start Date : February 2008
Actual Primary Completion Date : April 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Rosacea
MedlinePlus related topics: Rosacea
Drug Information available for: Tretinoin

Arm Intervention/treatment
Active Comparator: 1 Drug: tretinoin gel 0.05%
Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea

Placebo Comparator: 2 Drug: vehicle
Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.

Primary Outcome Measures :
  1. Improvement in signs and symptoms of rosacea [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Changes in various skin parameters [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female
  • Age 18-65
  • Diagnosed with classical, centrofacial, erythemato-telangiectatic rosacea

Exclusion Criteria:

  • Male, females less than 18 years
  • Females over 65 years
  • No diagnosed rosacea

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00621218

Layout table for location information
United States, Pennsylvania
Product Investigations, Inc.
Conshohocken, Pennsylvania, United States, 19428
Sponsors and Collaborators
Coria Laboratories, Ltd.
Layout table for investigator information
Principal Investigator: Morris V Shelanski, MD
Layout table for additonal information
Responsible Party: D. Innes Cargill, PhD, Coria Laboratories, Ltd.
ClinicalTrials.gov Identifier: NCT00621218    
Other Study ID Numbers: 9320-010-002
First Posted: February 22, 2008    Key Record Dates
Last Update Posted: December 18, 2008
Last Verified: December 2008
Keywords provided by Coria Laboratories, Ltd.:
tretinoin, efficacy, safety, rosacea
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Antineoplastic Agents
Keratolytic Agents
Dermatologic Agents